GEN Exclusives

More »

GEN News Highlights

More »
Oct 21, 2009

NKTT Gains Access to BioWa's Platform for Use in Antibody R&D

  • NKT Therapeutics (NKTT) is tapping into BioWa's Potelligent® Technology for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. NKTT will use this platform to research and develop antibodies targeting natural killer T cells. BioWa will receive an up-front payment, development milestone payments, and royalties on products.

    Potelligent reportedly improves potency and efficacy of antibody therapeutics by enhancing ADCC. It involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?